Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

569 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.
Guo J, Carvajal RD, Dummer R, Hauschild A, Daud A, Bastian BC, Markovic SN, Queirolo P, Arance A, Berking C, Camargo V, Herchenhorn D, Petrella TM, Schadendorf D, Sharfman W, Testori A, Novick S, Hertle S, Nourry C, Chen Q, Hodi FS. Guo J, et al. Among authors: hauschild a. Ann Oncol. 2017 Jun 1;28(6):1380-1387. doi: 10.1093/annonc/mdx079. Ann Oncol. 2017. PMID: 28327988 Free PMC article. Clinical Trial.
Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.
McArthur GA, Maio M, Arance A, Nathan P, Blank C, Avril MF, Garbe C, Hauschild A, Schadendorf D, Hamid O, Fluck M, Thebeau M, Schachter J, Kefford R, Chamberlain M, Makrutzki M, Robson S, Gonzalez R, Margolin K. McArthur GA, et al. Among authors: hauschild a. Ann Oncol. 2017 Mar 1;28(3):634-641. doi: 10.1093/annonc/mdw641. Ann Oncol. 2017. PMID: 27993793 Free article. Clinical Trial.
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.
Chapman PB, Robert C, Larkin J, Haanen JB, Ribas A, Hogg D, Hamid O, Ascierto PA, Testori A, Lorigan PC, Dummer R, Sosman JA, Flaherty KT, Chang I, Coleman S, Caro I, Hauschild A, McArthur GA. Chapman PB, et al. Among authors: hauschild a. Ann Oncol. 2017 Oct 1;28(10):2581-2587. doi: 10.1093/annonc/mdx339. Ann Oncol. 2017. PMID: 28961848 Free PMC article. Clinical Trial.
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Spieth K, Kaufmann R, Dummer R, Garbe C, Becker JC, Hauschild A, Tilgen W, Ugurel S, Beyeler M, Bröcker EB, Kaehler KC, Pföhler C, Gille J, Leiter U, Schadendorf D. Spieth K, et al. Among authors: hauschild a. Ann Oncol. 2008 Apr;19(4):801-6. doi: 10.1093/annonc/mdm565. Epub 2008 Jan 4. Ann Oncol. 2008. PMID: 18178958 Free article. Clinical Trial.
Utility of adjuvant systemic therapy in melanoma.
Eggermont AM, Testori A, Marsden J, Hersey P, Quirt I, Petrella T, Gogas H, MacKie RM, Hauschild A. Eggermont AM, et al. Among authors: hauschild a. Ann Oncol. 2009 Aug;20 Suppl 6(Suppl 6):vi30-4. doi: 10.1093/annonc/mdp250. Ann Oncol. 2009. PMID: 19617295 Free PMC article. Review.
Small molecules and targeted therapies in distant metastatic disease.
Hersey P, Bastholt L, Chiarion-Sileni V, Cinat G, Dummer R, Eggermont AM, Espinosa E, Hauschild A, Quirt I, Robert C, Schadendorf D. Hersey P, et al. Among authors: hauschild a. Ann Oncol. 2009 Aug;20 Suppl 6(Suppl 6):vi35-40. doi: 10.1093/annonc/mdp254. Ann Oncol. 2009. PMID: 19617296 Free PMC article. Review.
Immunotherapy of distant metastatic disease.
Schadendorf D, Algarra SM, Bastholt L, Cinat G, Dreno B, Eggermont AM, Espinosa E, Guo J, Hauschild A, Petrella T, Schachter J, Hersey P. Schadendorf D, et al. Among authors: hauschild a. Ann Oncol. 2009 Aug;20 Suppl 6(Suppl 6):vi41-50. doi: 10.1093/annonc/mdp253. Ann Oncol. 2009. PMID: 19617297 Free PMC article. Review.
569 results